Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila WST01
- Development stage
- Phase 2
- Lead developer
- Shanghai Sine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
WST01 is a specific strain of the Gram-negative, anaerobic bacterium *Akkermansia muciniphila* developed as a live biotherapeutic product (LBP) by Wanshengtai Biotechnology. It is primarily investigated for the treatment of metabolic disorders, including type 2 diabetes, obesity, and overweight conditions. *A. muciniphila* is a natural inhabitant of the human gut that resides in the mucus layer and plays a critical role in maintaining intestinal barrier integrity and metabolic homeostasis. WST01 supplementation aims to restore or increase the abundance of this bacterium in the gut, which has been linked to improved insulin sensitivity, reduced systemic inflammation, and increased secretion of glucagon-like peptide 1 (GLP-1). Clinical study results indicate that the efficacy of WST01 in reducing body weight and glycated hemoglobin (HbA1c) may be dependent on the patient's baseline levels of *Akkermansia* in the gut microbiota.
- Other names
- Akkermansia muciniphila strain WST01
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Akkermansia muciniphila WST01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila WST01.